Cargando…

Alzheimer's disease in Down syndrome: An overlooked population for prevention trials

The discovery that adults with Down syndrome (DS) have neuropathological features identical to individuals with sporadic Alzheimer's disease (AD) played a key role in the identification of the amyloid precursor protein gene on chromosome 21 and resulted in the amyloid cascade hypothesis. Indivi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strydom, André, Coppus, Antonia, Blesa, Rafael, Danek, Adrian, Fortea, Juan, Hardy, John, Levin, Johannes, Nuebling, Georg, Rebillat, Anne-Sophie, Ritchie, Craig, van Duijn, Cornelia, Zaman, Shahid, Zetterberg, Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296162/ https://www.ncbi.nlm.nih.gov/pubmed/30581976 http://dx.doi.org/10.1016/j.trci.2018.10.006

Ejemplares similares

The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer’s Disease
por: Rujeedawa, Tanzil, et al.
Publicado: (2021)

Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease
por: Aschenbrenner, Andrew J., et al.
Publicado: (2021)

Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review
por: Hamburg, Sarah, et al.
Publicado: (2019)

The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome
por: Dekker, Alain D., et al.
Publicado: (2018)

Overlooked in Fallon?
por: Daughton, Christian G.
Publicado: (2005)

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Montoliu-Gaya, Laia, et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Environmental health in Australia: overlooked and underrated
por: Whiley, H, et al.
Publicado: (2019)

Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome
por: Strydom, Andre, et al.
Publicado: (2018)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
por: Startin, Carla M., et al.
Publicado: (2019)

Three overlooked key functional classes for building up minimal synthetic cells
por: Danchin, Antoine
Publicado: (2021)

Postacute sequelae of SARS-CoV-2 infection. Osteonecrosis must not be overlooked
por: Koutalos, Antonios A., et al.
Publicado: (2022)

Alzheimer's disease diagnosis and management: Perspectives from around the world
por: Kerwin, Diana, et al.
Publicado: (2022)

Weight stigma is overlooked in commercial‐grade mobile applications for weight loss and weight‐related behaviors
por: Olson, KayLoni L., et al.
Publicado: (2020)

COVID-19 response in low- and middle-income countries: Don’t overlook the role of mobile phone communication
por: Verhagen, Lilly M., et al.
Publicado: (2020)

Von Willebrand Factor Activity in Thrombosis: An Overlooked Target for Intervention?
por: Shalmi, Theodor W., et al.
Publicado: (2021)

Plasma amino acids and neopterin in healthy persons with Down’s syndrome
por: Coppus, A. W., et al.
Publicado: (2007)

DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients
por: Moreau, Manon, et al.
Publicado: (2022)

Plasma levels of nitric oxide related amino acids in demented subjects with Down syndrome are related to neopterin concentrations
por: Coppus, A. M. W., et al.
Publicado: (2009)

Electronic Cigarettes: an Overlooked Tool to Alleviate Disparities in Tobacco Use Disorder Among People with Mental Health and Substance Use Disorders
por: Vuong, Jacqueline T., et al.
Publicado: (2023)

Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome
por: Startin, Carla M., et al.
Publicado: (2019)

Brain insulin resistance: an early risk factor for Alzheimer's disease development in Down syndrome
por: Barone, Eugenio
Publicado: (2021)

Association of biological sex with clinical outcomes and biomarkers of Alzheimer’s disease in adults with Down syndrome
por: Iulita, M Florencia, et al.
Publicado: (2023)

Structural Connectivity in Down Syndrome and Alzheimer’s Disease
por: Saini, Fedal, et al.
Publicado: (2022)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome
por: Bejanin, Alexandre, et al.
Publicado: (2021)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

Down to the bone: the role of overlooked endolithic microbiomes in reef coral health
por: Pernice, Mathieu, et al.
Publicado: (2019)

Participant outcomes and preferences in Alzheimer's disease clinical trials: The electronic Person-Specific Outcome Measure (ePSOM) development program
por: Saunders, Stina, et al.
Publicado: (2018)

Alzheimer’s disease in people with Down’s syndrome: the prospects for and the challenges of developing preventative treatments
por: Castro, Paula, et al.
Publicado: (2016)

Ups and downs in early electron cryo-microscopy
por: Dubochet, Jacques, et al.
Publicado: (2018)

The Minamata Convention and the phase down of dental amalgam
por: Fisher, Julian, et al.
Publicado: (2018)

Aging related cognitive changes associated with Alzheimer's disease in Down syndrome
por: Firth, Nicholas C., et al.
Publicado: (2018)

Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios
por: Bouwman, Femke H., et al.
Publicado: (2022)

Intracerebral haemorrhage in Down syndrome: protected or predisposed?
por: Buss, Lewis, et al.
Publicado: (2016)

Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study
por: Pentz, Rowan, et al.
Publicado: (2020)

‘Doubling down’ on the autophagy pathway to suppress tumor growth
por: Leidal, Andrew M., et al.
Publicado: (2014)

Down Syndrome and COVID-19: A Perfect Storm?
por: Espinosa, Joaquin M.
Publicado: (2020)

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study
por: Fortea, Juan, et al.
Publicado: (2020)

Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome()
por: Neale, Natalie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_m85nup5d0cqd4m9j6nbt8e7s4t